JP2022124458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022124458A5 JP2022124458A5 JP2021202780A JP2021202780A JP2022124458A5 JP 2022124458 A5 JP2022124458 A5 JP 2022124458A5 JP 2021202780 A JP2021202780 A JP 2021202780A JP 2021202780 A JP2021202780 A JP 2021202780A JP 2022124458 A5 JP2022124458 A5 JP 2022124458A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- formula
- compound according
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941.7 | 2019-12-10 | ||
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
| JP2021566023A JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566023A Division JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022124458A JP2022124458A (ja) | 2022-08-25 |
| JP2022124458A5 true JP2022124458A5 (enExample) | 2024-08-07 |
| JP7802514B2 JP7802514B2 (ja) | 2026-01-20 |
Family
ID=68848113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566023A Active JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
| JP2021202780A Active JP7802514B2 (ja) | 2019-12-10 | 2021-12-14 | 新規メチルキナゾリノン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566023A Active JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (enExample) |
| EP (2) | EP4483882A3 (enExample) |
| JP (2) | JP7108146B2 (enExample) |
| KR (1) | KR102836833B1 (enExample) |
| CN (2) | CN114787156B (enExample) |
| AR (1) | AR122351A1 (enExample) |
| AU (1) | AU2020403443B2 (enExample) |
| CL (1) | CL2022001529A1 (enExample) |
| CO (1) | CO2022008968A2 (enExample) |
| CR (1) | CR20220251A (enExample) |
| DK (1) | DK4073065T3 (enExample) |
| ES (1) | ES3023264T3 (enExample) |
| FI (1) | FI4073065T3 (enExample) |
| HR (1) | HRP20250418T1 (enExample) |
| HU (1) | HUE071148T2 (enExample) |
| IL (2) | IL316473A (enExample) |
| LT (1) | LT4073065T (enExample) |
| MA (1) | MA58087B1 (enExample) |
| MX (1) | MX2022006783A (enExample) |
| PE (1) | PE20221778A1 (enExample) |
| PH (1) | PH12022551119A1 (enExample) |
| PL (1) | PL4073065T3 (enExample) |
| PT (1) | PT4073065T (enExample) |
| RS (1) | RS66721B1 (enExample) |
| SI (1) | SI4073065T1 (enExample) |
| TW (2) | TWI877268B (enExample) |
| UA (1) | UA128299C2 (enExample) |
| WO (1) | WO2021116055A1 (enExample) |
| ZA (2) | ZA202204675B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158541A1 (en) * | 2019-12-10 | 2021-06-17 | Cosimo Dolente | New braf inhibitors as paradox breakers |
| SI4073065T1 (sl) | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| MX2022015703A (es) | 2020-06-09 | 2023-01-24 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| IL308015A (en) * | 2021-06-09 | 2023-12-01 | Hoffmann La Roche | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| CN117642166A (zh) * | 2021-06-09 | 2024-03-01 | 中外制药株式会社 | 用于癌症治疗的组合疗法 |
| JP2024522603A (ja) * | 2021-06-09 | 2024-06-21 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | （３ｒ）－ｎ－［２－シアノ－４－フルオロ－３－（３－メチル－４－オキソ－キナゾリン－６－イル）オキシ－フェニル］－３－フルオロ－ピロリジン－１－スルホンアミドの新規固形物 |
| EP4378478A4 (en) | 2021-07-27 | 2025-11-12 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| IL312171A (en) | 2021-11-04 | 2024-06-01 | Hoffmann La Roche | Innovative use of the quinazolinone compound for cancer treatment |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| JP2025537786A (ja) | 2022-11-18 | 2025-11-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 進行性固形がんまたは転移の治療のためのｂｒａｆ阻害剤としてのキナゾリノン化合物 |
| EP4634171A1 (en) * | 2022-12-15 | 2025-10-22 | F. Hoffmann-La Roche AG | Process for the preparation of a quinazolinone derivative |
| JP2025541200A (ja) * | 2022-12-15 | 2025-12-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん処置のための併用療法 |
| IL324898A (en) | 2023-07-04 | 2026-01-01 | Hoffmann La Roche | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinozolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
| WO2025108405A1 (zh) | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
| WO2026037755A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | New methylquinazolinone derivatives |
| WO2026046946A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| AU2009226136B2 (en) | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| CA2882410A1 (en) | 2012-09-19 | 2014-03-27 | Novartis Ag | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
| RU2015149937A (ru) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
| BR112017025045A2 (pt) | 2015-05-22 | 2018-08-07 | Plexxikon Inc | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 |
| PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| SI4073065T1 (sl) | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| CA3158541A1 (en) * | 2019-12-10 | 2021-06-17 | Cosimo Dolente | New braf inhibitors as paradox breakers |
| MX2022015703A (es) | 2020-06-09 | 2023-01-24 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| CN118561841A (zh) | 2020-12-18 | 2024-08-30 | 豪夫迈·罗氏有限公司 | 新的芳基-吡啶并-嘧啶-酮衍生物 |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| KR20240115893A (ko) | 2021-12-08 | 2024-07-26 | 어레이 바이오파마 인크. | N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태 |
-
2020
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
- 2020-12-09 TW TW113139852A patent/TWI908405B/zh active
-
2021
- 2021-12-14 JP JP2021202780A patent/JP7802514B2/ja active Active
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292161B1 (en) | New methylquinazolinone derivatives | |
| JP2017525730A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2015530389A5 (enExample) | ||
| JP2024514339A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2010270124A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| JP2016501882A5 (enExample) | ||
| RU2018108589A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr | |
| JP2016515561A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2016512563A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| JP2015500885A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| JP2014534269A5 (enExample) | ||
| JP2012522841A5 (enExample) |